Amag Pharmaceuticals (AMAG) Stock Overview
USA - NASDAQ:AMAG -
AMAG Key Statistics, Chart & Performance
The current stock price of AMAG is 13.75 null. In the past month the price increased by 0.88%. In the past year, price increased by 39.45%.
AMAG Latest News, Press Relases and Analysis
About AMAG
Company Profile
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Company Info
Amag Pharmaceuticals
1100 WINTER STREET
WALTHAM MA 02451
CEO: William K. Heiden
Phone: 617-498-3300
Amag Pharmaceuticals / AMAG FAQ
What does AMAG do?
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex', the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
What is the current price of AMAG stock?
The current stock price of AMAG is 13.75 null. The price increased by 0.15% in the last trading session.
What is the dividend status of Amag Pharmaceuticals?
AMAG does not pay a dividend.
What is the ChartMill technical and fundamental rating of AMAG stock?
AMAG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of Amag Pharmaceuticals (AMAG) based on its PE ratio?
Amag Pharmaceuticals (AMAG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.3).
Would investing in Amag Pharmaceuticals be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AMAG.
AMAG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AMAG. When comparing the yearly performance of all stocks, AMAG is one of the better performing stocks in the market, outperforming 88.08% of all stocks.
AMAG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AMAG. AMAG may be in some trouble as it scores bad on both profitability and health.
AMAG Financial Highlights
Over the last trailing twelve months AMAG reported a non-GAAP Earnings per Share(EPS) of -2.3. The EPS increased by 61.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -74.73% | ||
| ROA | -31% | ||
| ROE | N/A | ||
| Debt/Equity | 0.08 |